Total Payments
$3,263
2024 Payments
$47.62
Companies
21
Transactions
141
Medicare Patients
2,181
Medicare Billing
$588,606
Payment Breakdown by Category
Food & Beverage$3,051 (93.5%)
Education$177.68 (5.4%)
Other$33.93 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,051 | 134 | 93.5% |
| Education | $177.68 | 6 | 5.4% |
| Entertainment | $33.93 | 1 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $616.33 | 25 | $0 (2019) |
| Relypsa, Inc. | $345.55 | 16 | $0 (2019) |
| Amgen Inc. | $329.96 | 18 | $0 (2021) |
| Shire North American Group Inc | $290.50 | 15 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $279.52 | 15 | $0 (2021) |
| Mallinckrodt Enterprises LLC | $270.42 | 11 | $0 (2019) |
| OPKO Pharmaceuticals, LLC | $213.90 | 5 | $0 (2019) |
| Aurinia Pharma U.S., Inc. | $153.26 | 6 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $132.46 | 3 | $0 (2024) |
| GlaxoSmithKline, LLC. | $119.38 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47.62 | 2 | Aurinia Pharma U.S., Inc. ($28.82) |
| 2022 | $113.41 | 5 | Aurinia Pharma U.S., Inc. ($53.01) |
| 2021 | $367.20 | 13 | GlaxoSmithKline, LLC. ($119.38) |
| 2020 | $217.19 | 7 | Janssen Pharmaceuticals, Inc ($113.66) |
| 2019 | $997.53 | 39 | Otsuka America Pharmaceutical, Inc. ($214.21) |
| 2018 | $913.08 | 43 | Otsuka America Pharmaceutical, Inc. ($308.86) |
| 2017 | $606.63 | 32 | Relypsa, Inc. ($98.25) |
All Payment Transactions
141 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/28/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 08/14/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/22/2022 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Iron Deficiency Anemia | ||||||
| 05/26/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: Cardio-renal | ||||||
| 04/07/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $27.61 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 03/18/2022 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: Phosphate binder for ESRD | ||||||
| 03/10/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/13/2021 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $25.80 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/08/2021 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: Phosphate binder for ESRD | ||||||
| 12/07/2021 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/23/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $12.76 | General |
| Category: Cardio-renal | ||||||
| 11/08/2021 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $11.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/02/2021 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $25.96 | General |
| Category: Nephrology | ||||||
| 10/26/2021 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $25.94 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 10/19/2021 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Hyperkalemia | ||||||
| 10/02/2021 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Education | In-kind items and services | $19.69 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 09/28/2021 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: Hyperkalemia | ||||||
| 07/20/2021 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/14/2021 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $119.38 | General |
| Category: IMMUNOLOGY | ||||||
| 07/13/2021 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $24.58 | General |
| Category: Hyperkalemia | ||||||
| 03/06/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $105.35 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/06/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $8.31 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 02/20/2020 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/17/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/04/2020 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 183 | 261 | $37,434 | $23,226 |
| 2022 | 11 | 480 | 813 | $287,684 | $107,866 |
| 2021 | 12 | 739 | 1,561 | $648,831 | $236,601 |
| 2020 | 13 | 779 | 1,623 | $691,344 | $220,913 |
Total Patients
2,181
Total Services
4,258
Medicare Billing
$588,606
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 45 | 119 | $11,437 | $8,130 | 71.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 52 | 53 | $14,970 | $7,737 | 51.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 62 | 64 | $6,207 | $4,491 | 72.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 25 | $4,821 | $2,869 | 59.5% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 39 | 138 | $105,984 | $42,598 | 40.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 133 | 317 | $57,145 | $20,026 | 35.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 93 | 99 | $49,329 | $17,341 | 35.2% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 24 | 38 | $24,586 | $9,804 | 39.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 60 | 75 | $21,750 | $6,483 | 29.8% |
| 99220 | Initial hospital observation care per day, typically 70 minutes | Facility | 2022 | 30 | 31 | $10,521 | $4,802 | 45.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 18 | 30 | $5,940 | $1,893 | 31.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 35 | $6,825 | $1,849 | 27.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 22 | 22 | $2,090 | $1,352 | 64.7% |
| 99217 | Hospital observation care on day of discharge | Facility | 2022 | 15 | 15 | $1,455 | $917.85 | 63.1% |
| 99225 | Follow-up observation care per day, typically 25 minutes | Facility | 2022 | 13 | 13 | $2,059 | $800.44 | 38.9% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 63 | 374 | $287,232 | $114,604 | 39.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 212 | 542 | $106,774 | $34,553 | 32.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 155 | 172 | $96,320 | $30,621 | 31.8% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 41 | 73 | $47,231 | $18,800 | 39.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 89 | 161 | $46,690 | $16,961 | 36.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 63 | 94 | $18,330 | $6,100 | 33.3% |
| 99220 | Hospital observation care, typically 70 minutes | Facility | 2021 | 22 | 23 | $11,753 | $3,709 | 31.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 22 | 26 | $9,854 | $3,193 | 32.4% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 28 | 49 | $9,702 | $3,126 | 32.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $6,825 | $2,090 | 30.6% |
About Dr. David Trueba, M.D
Dr. David Trueba, M.D is a Nephrology healthcare provider based in Tavernier, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306876743.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Trueba, M.D has received a total of $3,263 in payments from pharmaceutical and medical device companies, with $47.62 received in 2024. These payments were reported across 141 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($3,051).
As a Medicare-enrolled provider, Trueba has provided services to 2,181 Medicare beneficiaries, totaling 4,258 services with total Medicare billing of $588,606. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Internal Medicine
- Location Tavernier, FL
- Active Since 07/03/2006
- Last Updated 10/25/2025
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1306876743
Products in Payments
- Veltassa (Drug) $414.50
- JYNARQUE (Drug) $378.04
- ACTHAR (Biological) $303.29
- NATPARA (Drug) $249.64
- LOKELMA (Drug) $246.45
- SAMSCA (Drug) $238.29
- Rayaldee (Drug) $213.90
- Repatha (Biological) $165.77
- LUPKYNIS (Drug) $153.26
- XARELTO (Drug) $132.46
- Parsabiv (Biological) $120.89
- BENLYSTA (Biological) $119.38
- INJECTAFER (Drug) $91.90
- Auryxia (Drug) $55.15
- Rituxan (Biological) $54.29
- GATTEX (Drug) $40.86
- Velphoro (Drug) $36.14
- RENVELA (Drug) $34.46
- NephroCheck Test (Device) $33.93
- FARXIGA (Drug) $33.07
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.